C12N 2710/10022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/10022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 42 US grants and 95 published applications in this corpus.
Search patents in C12N- Granted patents
- 42
- Published applications
- 95
- Assignees
- 66
- Inventors
- 183
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 2 | 1 |
| 2009 | 0 | 7 |
| 2010 | 1 | 0 |
| 2011 | 2 | 4 |
| 2012 | 1 | 2 |
| 2013 | 2 | 3 |
| 2014 | 1 | 3 |
| 2015 | 3 | 2 |
| 2016 | 2 | 7 |
| 2017 | 2 | 4 |
| 2018 | 3 | 2 |
| 2019 | 0 | 5 |
| 2020 | 5 | 6 |
| 2021 | 1 | 4 |
| 2022 | 4 | 3 |
| 2023 | 3 | 6 |
| 2024 | 1 | 11 |
| 2025 | 4 | 15 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Transient inhibition of p53 in gene therapy24 Feb 2026US 12,558,435 B2Fondazione Telethon Ets
- Desmoglein 2 (DSG2) binding proteins and uses therefor11 Nov 2025US 12,466,859 B2University of Washington through its Center for Commercialization
- Therapeutic pharmaceutical composition for bone and soft tissue tumors27 May 2025US 12,310,998 B2Surv BioPharma Inc.
- Viral gene therapy as treatment for cholesterol storage disease or disorder21 Jan 2025US 12,201,658 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Engineered adenovirus vectors and uses thereof8 Oct 2026US 2026/0308629 A1
- Protein and vaccine against infection by sars-cov-2 omicron variant strain and subtype thereof10 Sep 2026US 2026/0263587 A1Westvac Biopharma Co., Ltd.
- Packaging plasmids for aav production3 Sep 2026US 2026/0258449 A1Biogen MA Inc.
- Recombinant adenovirus comprising a polynucleotide encoding denv envelope protein and a polynucleotide encoding ferritin heavy chain protein, and uses thereof27 Aug 2026US 2026/0248902 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Oncolytic adenoviral vector and methods of use16 Apr 2026US 2026/0102445 A1Unleash Immuno Oncolytics, Inc.
Most cited
By later US patents
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use50US 8,105,574 B2The Trustees of the University of Pennsylvania · 2012
- Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof48US 8,834,863 B2The Trustees of the University of Pennsylvania · 2014
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use46US 8,603,459 B2The Trustees of the University of Pennsylvania · 2013
- Immortalized intestinal epithelial cell lines35US 5,811,281 ACornell Research Foundation, Inc. · 1998